ESMO 2022

Dose-dense standard of care is the optimal care

Immuntherapy only for low risk patients?

My highlights of ESMO22

Simple and cheap surgical technique may impact survival in early breast cancer

Endocrine response in eBC

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Dose-dense therapy is beneficial for all patients

Dose dense is better

Consolidating data from prospective studies

Long-term data on dose density therapy in chemotherapy

Roadmap for the adjuvant setting

QoL and longterm toxicity

DD is the champion!

Reduction of peripheral neuropathy with taxane therapy

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Il vincitore e’ il dose dense!!

I miei punti salienti di ESMO22

Schéma dose-dense bénéfique pour toutes les patientes

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

Datele trialurilor se consolideata

Status update - adjuvant IO. Are TILs prognostic?

How to deal with the negative SERD data?

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Tailoring Adjuvant Therapy

Unmeet needs and my wishes for 2022!

Negative and yet positive?!

Another option for heavily pre-treated HR+ advanced breast cancer patients

Interim analysis shows promising data on Abema in the 1st Line

Sacituzumab govitecan for everybody!

TROPiCS-02 highlights

CDK4/6i could be an option for selected ER+/HER2+ disease

OS not significant, but re-assuring new data

New treatment option for heavily pre-treated patients with ER+ MBC

Survival benefit from SG in mBC

Discontinued development

Survival benefit in endocrine sensitive patients

HER2+ and still without chemotherapy

SG is a novel treatment option for HR+/HER2- disease

ADC after ADC - is there any orientation?

My highlights of ESMO22

More therapy options for patients with HR+, HER2+ disease

VEX has no place in chemotherapy of metastatic breast cancer

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Exciting data, but Phase 3 studies are needed

Update on biomarkers on ADCs of the DAISY trial

The third in the bunch

I miei punti salienti di ESMO22

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Sacituzumab Govitecan: Un farmaco per tutte?

Survie globale pas encore significative statistiquement mais données rassurantes

TROPiCS-02 highlights

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Nouvelles données des analyses expolratoires dans l’étude DAISY

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Sopravvivenza globale nello studio MONARCH3

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

ADAURA Update - preventing relapse or just delaying it?

Window for treatment selection

Osimertinib - curing or delaying relapse?

Concurrent preoperative IO/CRT in early lung cancer

Long term follow-up of ADAURA trial

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Neoadjuvant strategies for PD-L1 < 1 %

ADAURA revisited

Osimertinib stays standard adjuvant

Is OS really needed?

Pollution and lung cancer - one mechanism revealed

INCREASE - to good to be true?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Pollution et cancer du poumon - un mécanisme mis en évidence

Eine Plattform für "take the winner"-Strategie

Langzeitdaten ADAURA

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Osimertinib: una cura o ritarda la ripresa di malattia?

ADAURA revisited

Osimertinib bleibt Standard adjuvant

Important data on borderline resectable patients

DFS matters!

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib vs. Docetaxel in mKRAS G12C

Can IO be discontinued?

A new step in treatment of KRAS G12C mutant NSCLC

Real-world data on Atezolizumab

Pneumonitis and T-DXd

Cemiplimab beyond progression?

Chemoimmunotherapy - improvement of survival after 5 years

The journey at KRAS G12C continues

Immunotherapy in unfit population? Perhaps...

Liquid biopsy monitoring in treatment decisions

HER2 - the next actionable mutation in lung cancer?

Preview on lung cancer highlights

Sotorasib: sweet and sour results

Induction chemoimmunotherapy in borderline resectability?

New therapy combination after progression on 1L osimertinib

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Poseidon and STK11/KEAP

Can we finally treat poor prognostic patients with immunotherapy?

DESTINY-Lung02 - better than the original?

Is shorter immunotherapy equally effective and less physically demanding?

Emerging IO mono options in the first line

Atezolizumab better than vinorelbin in reduced performance status

If you don't look, vou don't find - once you found it, you'll treat it!

One more brick in the KRAS G12C wall

Question about timing and duration of immunotherapy still unanswered

5-year data on survival under immunotherapy

Sotorasib - a new standard of care?

5-year update on 1st line chemoimmunotherapy

5 years of chemoimmunotherapy: solid grounded

New immunotherapy options for pts. ineligible to 1st line platinum therapy

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Die Reise bei KRAS G12C geht weiter

Atezo besser als Vino bei PS2-3

Cemiplimab beyond progression?

Poseidon und STK11/KEAP

Immunoterapia nella popolazione non fit: forse

5-Jahresüberleben mit Immuntherapie

IO-IO neoadjuvant bei PD-L1 neg.

Données de vie réelle avec l’atezolizumab

Resultados Agridulces de Sotorasib

5 Jahre Chemo-Immuntherapie: starker Effekt

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Neue Therapiekombination in der Resistenz nach Osimertinib

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Un mattone in piu' nel muro del KRAS G12C

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Les études incontournables à l’ESMO 2022

Sotorasib vs. Docetaxel bei mKRAS G12C

Pneumonitis und T-DXd

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Neue Option der IO-Therapie in der Erstlinie

Liquid Biopsy Monitoring zur Therapiesteuerung

Chimio-immunothérapie - amélioration de la survie après 5 ans

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Kann IO pausiert werden?

New strategies in immunotherapy

Heterogenity in the genetic landscape - little progress in molecular alterations

A positive study! With a question mark?

Novel data and long-term efficacy of chemo-IO in mNSCLC

Exciting data for high-risk patients: is this the start of a new era?

No value of IPI/Nivo in the adjuvant setting.

Brief highlights about RCC & urothelial cancer from ESMO22

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Immune-based peri-operative treatment in RCC: What went wrong?

Two negative studies question adjuvant approach in RCC

Place of triplet therapy

New combo - triplet therapy for kidney cancer

News in terms of adjuvant

Adjuvant Immuntherapy in kidney cancer

More questions being raised

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Terapia triple para cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Inmunoterapia adyuvante en el cancer renales

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Therapy combinations in RCC - what is the role of triplet therapy?

Immunomodulation in combination with checkpointinhibiton

Shedding light on TKI/Checkpointinhibitor combinations

EV + Pembro with excellent response rates

EV + pembrolizumab in cisplatin-ineligible patients

Brief highlights about RCC & urothelial cancer from ESMO22

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Promising data, but beware of toxicity

In older vulnerable - less is more

PSA at 8-months as a biomarker

Cabazitaxel better tolerated in elderly men

Combination of olaparib leads to promising results

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Length of hormone therapy after radiation

Triplet therapy with darolutamide in prostate cancer

Further evaluation of PSA correlates

IO + PARP without benefit in the allcomer situation

Radicals - ADT & Radiotherapy

Update on the PROpel study

Genetic testing before PARP therapy is useful

Biomarker data for better patients selection

ADT + ENZA better choice than monotherapy

Optimizing cabazitaxel chemotherapy

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

ADCs - a possible therapeutic approach

QoL data from ARASENS triplet therapy study mHRPC

Uppdatering i PROpel studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Livskvalitetsuppföljning i ARASENS studien

Intimate partner violence in cancer patients

Addition of CPI to Radiochemotherapy in LA-HNSCC?

Novel approach von Biontech towards Cancer – game changing potential?!

New group of substances for rare diseases

TILs - Fashion is the eternal return of the old

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy